Affiliation:
1. INSERM, Centre de Recherche des Cordeliers Sorbonne Université Paris France
2. Diabetology Department, Assistance Publique‐Hôpitaux de Paris (APHP) La Pitié‐Salpêtrière‐Charles Foix University Hospital Paris France
3. Institut Hospitalo‐Universitaire ICAN Paris France
4. Institut des Neurosciences Paris‐Saclay, CNRS UMR 9197 Université Paris‐Saclay France
Abstract
Cardiometabolic disorders contribute to the global burden of cardiovascular diseases. Emerging sphingolipid metabolites like sphingosine‐1‐phosphate (S1P) and its receptors, S1PRs, present a dynamic signalling axis significantly impacting cardiac homeostasis. S1P's intricate mechanisms extend to its transportation in the bloodstream by two specific carriers: high‐density lipoprotein particles and albumin. This intricate transport system ensures the accessibility of S1P to distant target tissues, influencing several physiological processes critical for cardiovascular health. This review delves into the diverse functions of S1P and S1PRs in both physiological and pathophysiological conditions of the heart. Emphasis is placed on their diverse roles in modulating cardiac health, spanning from cardiac contractility, angiogenesis, inflammation, atherosclerosis and myocardial infarction. The intricate interplays involving S1P and its receptors are analysed concerning different cardiac cell types, shedding light on their respective roles in different heart diseases. We also review the therapeutic applications of targeting S1P/S1PRs in cardiac diseases, considering existing drugs like Fingolimod, as well as the prospects and challenges in developing novel therapies that selectively modulate S1PRs.
Funder
Agence Nationale de la Recherche
Société Francophone du Diabète